Faced with the constant threat of exposure to the coronavirus at great risk to their own health, healthcare professionals (HCPs) working on the front lines of the pandemic can also inadvertently put other patients and co-workers at risk of infection.

In this global fight against COVID-19, MeMed BV™ could potentially help to:

 

• Identify presymptomatic and asymptomatic carriers and reduce the spread of infection

• Avoid unnecessary isolations to ease the burden of staff shortages at this critical time

• Enable early treatment of physicians, nurses and other front-line healthcare workers

MeMed BV™ measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. The test accurately distinguishes between viral and bacterial infections with over 90% sensitivity and specificity (96% NPV) across multiple pathogens, times from symptom onset, and irrespective of colonizers.1–4

 

Two of MeMed BV's proteins, TRAIL and IP-10, are viral biomarkers. They have been shown to signal a viral infection, and also predict disease severity when integrated with a proprietary Severity Score™ algorithm. The Severity Score™ may help in the management of the COVID-19 outbreak within hospitals and medical centers, through the objective evaluation of the potential severity of an early-stage infection in patients, HCPs, and other members of the community, to COVID-19. For example, MeMed BV can be used as a tool to:

 

• Help clinicians decide if extensive medical intervention is warranted

• Identify patients who may be safely discharged from the hospital and instructed to self-isolate in their homes 

• Monitor patients' ongoing response to treatment  

References

1. Oved, K. et al. A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections. PLoS ONE, e0120012 (2015).

2. van Houten, C. B. et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect Dis (2016) doi:10.1016/S1473-3099(16)30519-9.

3. Srugo, I. et al. Validation of a Novel Assay to Distinguish Bacterial and Viral Infections. Pediatrics e20163453 (2017) doi:10.1542/peds.2016-3453.

4. Ashkenazi-Hoffnung, L. et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. Eur. J. Clin. Microbiol. Infect. Dis. (2018) doi:10.1007/s10096-018-3261-3.